TACI靶向CAR-T(Massachusetts General Hospital)(TACI targeting CAR T(Massachusetts General Hospital)) - 药物靶点：TACI_在研适应症：多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

CAR-T

别名-

靶点

TACI

作用机制

TACI modulators(Tumor necrosis factor receptor superfamily member 13B modulators)

治疗领域

肿瘤免疫系统疾病心血管疾病+ [1]

在研适应症

多发性骨髓瘤

非在研适应症-

原研机构

The Massachusetts General Hospital

在研机构

The Massachusetts General Hospital

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 TACI靶向CAR-T(Massachusetts General Hospital) 相关的临床结果

登录后查看更多信息

100 项与 TACI靶向CAR-T(Massachusetts General Hospital) 相关的转化医学

登录后查看更多信息

100 项与 TACI靶向CAR-T(Massachusetts General Hospital) 相关的专利（医药）

登录后查看更多信息

1

项与 TACI靶向CAR-T(Massachusetts General Hospital) 相关的文献（医药）

Nature Communications1区 · 综合性期刊

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma

1区 · 综合性期刊

ArticleOA

作者: Larson, Rebecca C ; Almazan, Antonio J ; Bouffard, Amanda A ; Berger, Trisha R ; Castano, Ana P ; Schmidts, Andrea ; Lee, Won-Ho ; Takei, Hana N ; Kann, Michael C ; Frigault, Matthew J ; Maus, Marcela V ; Scarfó, Irene ; Mount, Christopher W ; Gallagher, Kathleen M E ; Graham, Charlotte

AbstractChimeric Antigen Receptor (CAR) T cells directed to B cell maturation antigen (BCMA) mediate profound responses in patients with multiple myeloma, but most patients do not achieve long-term complete remissions. In addition, recent evidence suggests that high-affinity binding to BCMA can result in on-target, off-tumor activity in the basal ganglia and can lead to fatal Parkinsonian-like disease. Here we develop CAR T cells against multiple myeloma using a binder to targeting transmembrane activator and CAML interactor (TACI) in mono and dual-specific formats with anti-BCMA. These CARs have robust, antigen-specific activity in vitro and in vivo. We also show that TACI RNA expression is limited in the basal ganglia, which may circumvent some of the toxicities recently reported with BCMA CARs. Thus, single-targeting TACI CARs may have a safer toxicity profile, whereas dual-specific BCMA-TACI CAR T cells have potential to avoid the antigen escape that can occur with single-antigen targeting.

100 项与 TACI靶向CAR-T(Massachusetts General Hospital) 相关的药物交易

登录后查看更多信息